Cardiff Oncology, Inc.
CRDF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $683 | $488 | $386 | $359 |
| % Growth | 40% | 26.4% | 7.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $683 | $488 | $386 | $359 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $36,852 | $32,857 | $27,107 | $17,376 |
| G&A Expenses | $12,482 | $13,043 | $13,181 | $11,838 |
| SG&A Expenses | $12,482 | $13,043 | $13,181 | $11,838 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $49,334 | $45,900 | $40,288 | $29,214 |
| Operating Income | -$48,651 | -$45,412 | -$39,902 | -$28,855 |
| % Margin | -7,123.1% | -9,305.7% | -10,337.3% | -8,037.6% |
| Other Income/Exp. Net | $3,220 | $3,971 | $1,198 | $564 |
| Pre-Tax Income | -$45,431 | -$41,441 | -$38,704 | -$28,291 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$45,431 | -$41,441 | -$38,704 | -$28,291 |
| % Margin | -6,651.7% | -8,492% | -10,026.9% | -7,880.5% |
| EPS | -0.95 | -0.93 | -0.89 | -0.73 |
| % Growth | -2.2% | -4.5% | -21.9% | – |
| EPS Diluted | -0.95 | -0.93 | -0.89 | -0.73 |
| Weighted Avg Shares Out | 47,650 | 44,677 | 43,600 | 39,030 |
| Weighted Avg Shares Out Dil | 47,650 | 44,677 | 43,600 | 39,030 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,259 | $4,069 | $1,581 | $264 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $404 | $398 | $236 | $451 |
| EBITDA | -$48,247 | -$45,014 | -$39,666 | -$28,404 |
| % Margin | -7,064% | -9,224.2% | -10,276.2% | -7,912% |